Illumina, Inc.
General ticker "ILMN" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $20.4B (TTM average)
Illumina, Inc. follows the US Stock Market performance with the rate: 51.8%.
Estimated limits based on current volatility of 2.6%: low 260.66$, high 274.51$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 amc
- Company included in S&P500 list
- Total employees count: 8600 (-4.1%) as of 2025
- US accounted for 51.8% of revenue in the fiscal year ended 2025-12-28
- Current price 64.3% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-28 to 2027-12-28
- 2025-12-28 to 2026-12-28 estimated range: [109.67$, 159.81$]
- 2026-12-28 to 2027-12-28 estimated range: [109.73$, 161.34$]
Financial Metrics affecting the ILMN estimates:
- Positive: with PPE of 27.7 at the end of fiscal year the price was neutral
- Positive: 4.90 < Operating cash flow per share per price, % of 5.19
- Positive: 15.80 < Operating profit margin, % of 18.62
- Positive: Interest expense per share per price, % of 0.49 <= 0.75
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.34 > 10.70
- Positive: -51.61 < Industry operating profit margin (median), % of -17.52
- Positive: Inventory ratio change, % of 0.74 <= 1.34
- Positive: Industry inventory ratio change (median), % of -0.03 <= 0
- Positive: 34.41 < Shareholder equity ratio, % of 40.98 <= 42.26
Short-term ILMN quotes
Relationship graph
Long-term ILMN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-29 | 2025-12-28 |
|---|---|---|---|
| Operating Revenue | $4,484.00MM | $4,828.00MM | $4,333.00MM |
| Operating Expenses | $5,553.00MM | $5,661.00MM | $3,526.00MM |
| Operating Income | $-1,069.00MM | $-833.00MM | $807.00MM |
| Non-Operating Income | $-48.00MM | $-346.00MM | $279.00MM |
| Interest Expense | $77.00MM | $100.00MM | $101.00MM |
| R&D Expense | $1,354.00MM | $1,169.00MM | $967.00MM |
| Income(Loss) | $-1,117.00MM | $-1,179.00MM | $1,086.00MM |
| Taxes | $44.00MM | $44.00MM | $236.00MM |
| Net Income(Loss)* | $-1,161.00MM | $-1,223.00MM | $850.00MM |
| Stockholders Equity | $5,745.00MM | $2,373.00MM | $2,723.00MM |
| Inventory | $587.00MM | $547.00MM | $564.00MM |
| Assets | $10,111.00MM | $6,303.00MM | $6,644.00MM |
| Operating Cash Flow | $478.00MM | $837.00MM | $1,079.00MM |
| Capital expenditure | $195.00MM | $128.00MM | $148.00MM |
| Investing Cash Flow | $-231.00MM | $-178.00MM | $-55.00MM |
| Financing Cash Flow | $-1,210.00MM | $-570.00MM | $-744.00MM |
| Earnings Per Share** | $-7.35 | $-7.69 | $5.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.